Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Sep:123:130-142.
doi: 10.1016/j.phrs.2017.07.009. Epub 2017 Jul 14.

Arenobufagin inhibits prostate cancer epithelial-mesenchymal transition and metastasis by down-regulating β-catenin

Liping Chen  1 , Weiqian Mai  1 , Minfeng Chen  1 , Jianyang Hu  1 , Zhenjian Zhuo  2 , Xueping Lei  1 , Lijuan Deng  1 , Junshan Liu  3 , Nan Yao  1 , Maohua Huang  1 , Yinghui Peng  1 , Wencai Ye  4 , Dongmei Zhang  5
Affiliations
Free article

Arenobufagin inhibits prostate cancer epithelial-mesenchymal transition and metastasis by down-regulating β-catenin

Liping Chen et al. Pharmacol Res. 2017 Sep.
Free article

Erratum in

Abstract

Epithelial-mesenchymal transition (EMT) plays an important role in prostate cancer (PCa) metastasis; thus, developing EMT inhibitors may be a feasible treatment for metastatic PCa. Here, we discovered that arenobufagin and four other bufadienolides suppressed PC3 cell EMT. These compounds modulated EMT marker expression with elevating E-cadherin and reducing ZEB1, vimentin and slug expression, and attenuated the migration and invasion of PC3 cells. Among these five compounds, arenobufagin exhibited the most potent activity. We found that the mRNA and protein expression of β-catenin and β-catenin/TCF4 target genes, which are related to tumor invasion and metastasis, were down-regulated after arenobufagin treatment. Overexpression of β-catenin in PC3 cells antagonized the EMT inhibition effect of arenobufagin, while silencing β-catenin with siRNA enhanced the inhibitory effect of arenobufagin on EMT. In addition, arenobufagin restrained xenograft tumor EMT, as demonstrated by decreased mesenchymal marker expression and increased epithelial marker expression, and reduced the tumor metastatic foci in lung. This study demonstrates a novel anticancer activity of arenobufagin, which inhibits PC3 cell EMT by down-regulating β-catenin, thereby reducing PCa metastasis. In addition, it also provides new evidence for the development of arenobufagin as a treatment for metastatic prostate cancer.

Keywords: 19-oxocinobufotalin (PubChem CID: 102093790); Arenobufagin; Arenobufagin (PubChem CID: 12305198); Bufadienolides; Bufarenogin (PubChem CID: 167607); Cinobufotalin (PubChem CID: 259776); EMT; Metastatic prostate cancer; β-catenin.

PubMed Disclaimer

Comment in

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

MeSH terms